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ORIGINAL ARTICLE

Prevalent Vertebral Fractures Among Children
Initiating Glucocorticoid Therapy for the
Treatment of Rheumatic Disorders
A. M. HUBER,1 I. GABOURY,2 D. A. CABRAL,3 B. LANG,1 A. NI,4 D. STEPHURE,5 S. TABACK,6
P. DENT,7 J. ELLSWORTH,8 C. LEBLANC,8 C. SAINT-CYR,9 R. SCUCCIMARRI,10 J. HAY,11 B. LENTLE,3
M. MATZINGER,2 N. SHENOUDA,2 D. MOHER,2 F. RAUCH,10 K. SIMINOSKI,8 L. M. WARD,2 AND THE
CANADIAN STEROID-ASSOCIATED OSTEOPOROSIS IN THE PEDIATRIC POPULATION (STOPP)
CONSORTIUM

Objective. Vertebral fractures are an under-recognized problem in children with inﬂammatory disorders. We studied
spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating
glucocorticoid therapy.
Methods. Children were categorized as follows: juvenile dermatomyositis (n ⴝ 30), juvenile idiopathic arthritis (n ⴝ 28),
systemic lupus erythematosus and related conditions (n ⴝ 26), systemic arthritis (n ⴝ 22), systemic vasculitis (n ⴝ 16),
and other conditions (n ⴝ 12). Thoracolumbar spine radiograph and dual x-ray absorptiometry for lumbar spine (L-spine)
areal bone mineral density (BMD) were performed within 30 days of glucocorticoid initiation. Genant semiquantitative
grading was used for vertebral morphometry. Second metacarpal morphometry was carried out on a hand radiograph.
Clinical factors including disease and physical activity, calcium and vitamin D intake, cumulative glucocorticoid dose,
underlying diagnosis, L-spine BMD Z score, and back pain were analyzed for association with vertebral fracture.
Results. Thirteen vertebral fractures were noted in 9 children (7%). Of these, 6 patients had a single vertebral fracture
and 3 had 2–3 fractures. Fractures were clustered in the mid-thoracic region (69%). Three vertebral fractures (23%) were
moderate (grade 2); the others were mild (grade 1). For the entire cohort, mean ⴞ SD L-spine BMD Z score was
signiﬁcantly different from zero (ⴚ0.55 ⴞ 1.2, P < 0.001) despite a mean height Z score that was similar to the healthy
average (0.02 ⴞ 1.0, P ⴝ 0.825). Back pain was highly associated with increased odds for fracture (odds ratio 10.6 [95%
conﬁdence interval 2.1–53.8], P ⴝ 0.004).
Conclusion. In pediatric rheumatic conditions, vertebral fractures can be present prior to prolonged glucocorticoid
exposure.

There is increasing recognition that juvenile-onset inﬂammatory rheumatic conditions are associated with adverse
effects on the developing skeleton. Reductions in lumbar
spine (L-spine), femoral neck, and distal radial bone min-

eral density (BMD) in children with juvenile idiopathic
arthritis (JIA) have been consistently documented among
those who have been treated with glucocorticoids (1–13)
and those who have not (1– 6,8,9,12,14 –16). Reduced Lspine BMD has also been shown in children with juvenile
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dermatomyositis (DM) (17–21) and in juvenile systemic
lupus erythematosus (SLE) (3,21–27).
Vertebral and extremity fractures have also been described in pediatric rheumatic disease. An increase in
extremity fractures among children with arthritis has been
documented through a large, population-based retrospective study (28). Furthermore, vertebral fracture prevalence
ranging from 10% to 50% has been shown in crosssectional studies of children with prolonged rheumatic
disease durations and/or glucocorticoid exposure
(11,25,29,30). These cross-sectional reports have been important in highlighting the extent of spine morbidity in the
years following diagnosis. However, the timing of vertebral fracture onset remains unknown. In addition, many of
the previously reported children with vertebral fractures
were treated with glucocorticoids and other potentially
osteotoxic medications, making it difﬁcult to determine
whether the observed fractures and reductions in BMD
were related to the underlying disease, glucocorticoid
therapy, or other factors.
Our goal was to document the prevalence of vertebral
fractures within 30 days of glucocorticoid initiation in an
inception cohort of glucocorticoid-treated children with
rheumatic disorders. In addition, we sought to determine
the relationship between vertebral fractures and relevant
clinical factors, including spine BMD, underlying diagnosis, disease activity, age, pubertal stage, sex, back pain,
calcium and vitamin D intake, and physical activity.

PATIENTS AND METHODS
Patients and study design. Patients were recruited
through the Canadian Steroid-Associated Osteoporosis in
the Pediatric Population (STOPP) research initiative, a
national research program that studies bone morbidity in
children with chronic illnesses. Patients from 1 month to
17 years of age were enrolled (n ⫽ 134) between January 1,
2005 and December 31, 2007 in 10 participating tertiary
care children’s hospitals. Patients were enrolled within 30
days of ﬁrst-time glucocorticoid treatment for inﬂammatory rheumatic conditions, including juvenile DM, juvenile SLE, JIA (all subtypes), systemic pediatric vasculitides
(excluding Henoch-Schönlein purpura and Kawasaki disease), juvenile scleroderma (both systemic and localized),
and overlap syndromes (including mixed connective tissue disease). Diagnoses were made by university-afﬁliated
pediatric rheumatologists.
Children were excluded if glucocorticoids had previ-
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ously been used at any time for treatment of the underlying
disease. Patients were also excluded if they had received
intravenous or oral glucocorticoids for ⬎14 consecutive
days in the 12 months preceding study enrollment to treat
any other medical condition (e.g., asthma). Patients who
had received prior medication for osteoporosis (OP) were
also excluded, as were those who had received previous
treatment with calcium and/or vitamin D supplementation
that exceeded the Dietary Reference Intake (DRI) for their
age (31). Because this study involved radiation from dual
x-ray absorptiometry (DXA) and skeletal radiographs, girls
were excluded if they were pregnant or menstruating and
unwilling to use medically approved contraception. The
study was approved by the Research Ethics Board in each
institution and informed consent and/or assent was obtained prior to study enrollment.
Clinical data. The decision to initiate glucocorticoids
was made clinically prior to consideration for study enrollment. Demographic and anthropometric data were recorded using standard methods. Height, weight, and body
mass index (BMI; weight in kilograms divided by height in
meters squared) raw values were transformed into age- and
sex-matched Z scores according to the US Centers for
Disease Control and Prevention National Center for Health
Statistics normative database (32); for children ⬍2 years of
age, BMI Z scores were calculated according to the World
Health Organization Child Growth Standards (33). Pubertal staging was carried out according to the methods of
Marshall and Tanner (34,35). The presence or absence of
reported back pain at the time of diagnosis was recorded,
and the spine was palpated for tenderness over the posterior spinous processes (T4 –L4). Time since diagnosis and
time since symptom onset to the L-spine BMD assessment
were recorded. Children were divided into subgroups to
facilitate characterization of the cohort, as follows: juvenile DM, JIA (excluding systemic arthritis), juvenile SLE
and related conditions, systemic arthritis, systemic vasculitis (SV), and other conditions.
Assessment of calcium and vitamin D intake. Calcium
and vitamin D intake were assessed by a validated food
frequency questionnaire (36). Intake for each nutrient was
expressed as the percent of the adequate intake value
based on the DRIs (31). Calcium and vitamin D intake by
supplementation was added to the dietary intake to arrive
at a total daily intake for both nutrients. The percentage
scores were then classiﬁed as ⬍50% of the age-related DRI,
50 –100% of the DRI, and ⬎100% of the DRI.
Physical activity assessment. The Habitual Activity Estimation Scale is a validated, self/proxy report that provides an estimation of the intensity and duration of physical activity over a single day (37,38). Activity was
reported for both a typical weekday and a typical weekend
day in the previous 3 months. Activity classiﬁcations were
as follows: inactive (e.g., lying down), somewhat inactive
(e.g., sitting), somewhat active (e.g., walking), and very
active (e.g., running). Total inactive and total active times
were determined by summing the 2 inactive and the 2
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active categories for each of the weekend and weekday
reports.
Physician’s global assessment of disease activity according to a visual analog scale (VAS). There is no assessment tool that has been shown to allow comparison of
disease activity across rheumatic conditions. However, the
use of a VAS completed by a physician who is an expert in
the assessment of pediatric rheumatic conditions has been
validated in a variety of rheumatic conditions in the pediatric setting (39 – 41). Disease activity was scored according to a VAS by the patients’ attending rheumatologists,
measuring physician’s global assessment of disease activity. The VAS was represented by a 10-cm scale, where 0 ⫽
inactive disease and 10 ⫽ extremely active disease. Erythrocyte sedimentation rate was also measured, using standard methodology from the local laboratories.
L-spine BMD by DXA. BMD was measured in the anteroposterior direction at the L-spine (L1–L4) by DXA using either Hologic machines (QDR 4500 at 3 centers, Discovery at 2 centers, and Delphi at 1 center; Hologic,
Waltham, MA) or Lunar Prodigy (4 centers; GE Medical
Systems, Madison, WI). The machines were cross-calibrated as previously described (42). The primary outcome
for the study was L-spine BMD Z score; raw L-spine BMD
results were transformed to Z scores using the Hologic 12.4
normative database provided by the manufacturer, which
comprises the full age range of the children enrolled in the
study. In vivo precision for L-spine BMD was available in
8 of 10 centers and ranged from 0.003 to 0.017 gm/cm2.
Bone age and second metacarpal morphometry. Radiographs of the left hand and wrist for bone age were read
independently by 2 pediatric radiologists (NS, MM) according to Greulich and Pyle (43). If results for the 2
examiners were within 12 months of each other, the average of the 2 readings was used. For results that differed by
⬎12 months (n ⫽ 10), a third reader (LMW) who was
blinded to the results of the ﬁrst 2 adjudicated the discrepant reports. The intraclass correlation coefﬁcient (ICC) was
0.99 (95% conﬁdence interval [95% CI] 0.986 – 0.993) between the 2 initial examiners. The radiographs were also
evaluated for the possibility of rickets.
Using the same hand radiographs, a single observer measured the second metacarpal length, midshaft periosteal
diameter, and inner diameter, as previously described
(44), for derivation of the following indices: combined
cortical thickness, cortical area, percentage cortical area,
and inner diameter area. Indices were converted into ageand sex-matched Z scores as previously described (45).
The intraobserver reliability scores assessed by ICC were
1.0 (95% CI 0.999 –1.0), 0.99 (95% CI 0.986 – 0.997), and
0.89 (95% CI 0.777– 0.945) for the metacarpal length, outer
diameter, and inner diameter, respectively.
Vertebral morphometry. The Genant semiquantitative
method for vertebral morphometry was performed in the
following manner. Vertebral bodies were ﬁrst assigned a
severity score of grade 0 –3, where 0 ⫽ normal, 1 ⫽ mild,

Huber et al
2 ⫽ moderate, and 3 ⫽ severe. The morphometric grading
corresponded to the extent of the reduction in height ratios
when the anterior vertebral height was compared with the
posterior height (wedge fracture), the middle height with
the posterior height (biconcave fracture), and the posterior
height with the posterior height of the adjacent vertebral
bodies (crush fracture). The scores corresponded to the
following reduction in height ratios: grade 0, ⱕ20%; grade
1, ⬎20% to 25%; grade 2, ⬎25% to 40%; and grade 3,
⬎40%. Grade 0 was considered to be normal and higher
grades were considered to be a fracture. Minimal physiologic rounding of vertebral bodies in the mid-thoracic region of the spine, as can be seen in normal children, was
assigned a score of grade 0 (46).
Vertebral fracture assessment was carried out independently by 2 radiologists (NS, MM) from T4 to L4 (42,47).
Discrepancies between the ﬁrst 2 readers were resolved by
a third expert radiologist (BL), who was blinded to the
results of the other 2. The interobserver reliability for the
ﬁrst 2 readers according to Cohen’s kappa was 0.44 (95%
CI 0.28 – 0.59) when Genant grade 0 scores were compared
with grades 1, 2, and 3 combined. For grades 0 and 1
combined compared with grades 2 and 3 combined, the
Cohen’s kappa was 0.66 (95% CI 0.46 – 0.87).
Statistical analyses. Analyses were conducted using
SPSS, version 16.0 (SPSS, Chicago, IL). The presented P
values were 2-sided. To account for multiple comparisons,
a Bonferroni correction was applied to the univariate analyses. Categorical variables were summarized using frequencies and percentages. Normally distributed continuous variables were summarized using means and SDs.
Non-normally distributed continuous variables were summarized using medians and ranges. Z score variables were
compared against the healthy average (Z score ⫽ 0.0) using
a 1-sample Student’s t-test to assess whether the patient
population signiﬁcantly differed from the normal reference values. Proportions and 95% CIs were calculated
using the Wilson score method (48). The Mann-Whitney
test or Fisher’s exact test was used to compare patients
with and without fracture. The comparison of combined
cortical thickness Z score between patients with and without fracture was adjusted for metacarpal length Z score
using linear regression.
Univariate logistic regressions were performed to identify clinical parameters that were associated with the presence of vertebral fractures. Multiple logistic regression was
not performed due to the small number of vertebral fracture events. Univariate linear regressions were similarly
performed to identify the factors associated with L-spine
BMD Z score. To adjust for bone size, height Z score was
included in all linear regression on L-spine BMD Z score
models (both univariate and multivariate analysis). The
following variables were included in a clinically-driven,
multiple linear regression model that sought to determine
associations between relevant factors and L-spine BMD Z
score: sex, height Z score, BMI Z score, pubertal stage
(Tanner stage 1 versus 2–5), time since symptom onset,
disease activity, cumulative glucocorticoid dose in prednisone equivalents, diagnosis, and vitamin D intake. The

24 (80)
6 (20)
6.8 (1.4–15.5)
0.07 ⫾ 1.0
6.2 ⫾ 2.8
17.0 (2–109)
19 (1–357)
124 (27–742)
42 (0–86)
0 (0–7)
2,334 ⫾ 2,184
17.0 ⫾ 9.5
15.8 ⫾ 10.0
⫺1.06 ⫾ 1.0
⫺1.01 ⫾ 0.8

5.6 ⫾ 2.8
33.0 (0–133)
22 (1–4,900)
145 (17–5,110)
46 (0–97)
1.0 (0–17)
1,404 ⫾ 1,690
16.5 ⫾ 8.6
16.7 ⫾ 8.7
⫺0.55 ⫾ 1.2
⫺0.60 ⫾ 1.0

⫺0.11 ⫾ 1.0
0.03 ⫾ 1.2
0.19 ⫾ 1.2

18 (60)
7.3 (1.9–15.1)

69 (53)
62 (47)
10.0 (1.1–17.5)
⫺0.05 ⫾ 1.0

0.02 ⫾ 1.0
0.28 ⫾ 1.2
0.37 ⫾ 1.2

87 (65)
10.0 (1.4–16.9)

Juvenile DM
(n ⴝ 30)

⫺0.71 ⫾ 1.4
⫺0.70 ⫾ 1.2

460 ⫾ 797
17.9 ⫾ 7.4
18.6 ⫾ 7.1

1.4 (0–11)

51 (0–91)

36.0 (5–106)
32 (1–4,900)
353 (30–5,110)

5.3 ⫾ 2.6

9 (35)
17 (65)
12.9 (3.0–16.0)
0.19 ⫾ 1.3

⫺0.23 ⫾ 1.1
0.07 ⫾ 1.2
0.23 ⫾ 1.1

18 (64)
12.2 (3.7–16.9)

JIA
(n ⴝ 28)

0.06 ⫾ 1.1
⫺0.22 ⫾ 0.9

1,647 ⫾ 1,643
17.5 ⫾ 9.0
16.0 ⫾ 9.4

0 (0–17)

38 (0–97)

47.5 (7–116)
16 (1–235)
67 (17–765)

4.7 ⫾ 2.9

7 (27)
19 (73)
14.5 (4.6–16.5)
⫺0.50 ⫾ 1.0

⫺0.17 ⫾ 0.8
0.28 ⫾ 1.0
0.46 ⫾ 0.9

22 (85)
13.6 (5.0–16.1)

SLE and related
conditions
(n ⴝ 26)

⫺0.63 ⫾ 0.8
⫺0.57 ⫾ 1.0

762 ⫾ 1,159
16.5 ⫾ 7.7
15.5 ⫾ 8.7

0.9 (0–8)

52 (0–83)

58.5 (10–133)
22 (1–64)
50 (18–225)

6.3 ⫾ 2.0

15 (68)
7 (32)
5.9 (1.1–17.0)
0.06 ⫾ 0.5

0.28 ⫾ 1.1
0.29 ⫾ 1.0
0.23 ⫾ 1.3

13 (59)
6.0 (1.4–16.4)

Systemic arthritis
(n ⴝ 22)

⫺0.70 ⫾ 1.5
⫺0.76 ⫾ 1.3

1,680 ⫾ 1,693
18.4 ⫾ 7.8
17.1 ⫾ 7.5

0.4 (0–5)

36 (0–78)

47.0 (1–109)
21 (1–132)
138 (24–975)

6.1 ⫾ 3.7

7 (44)
9 (56)
13.8 (3.3–17.0)
⫺0.01 ⫾ 1.4

0.42 ⫾ 1.2
0.77 ⫾ 1.4
0.69 ⫾ 1.3

8 (50)
12.6 (4.7–16.9)

Systemic vasculitis
(n ⴝ 16)

0.04 ⫾ 0.8
⫺0.02 ⫾ 0.85

1,477 ⫾ 1,417
7.7 ⫾ 6.6
19.3 ⫾ 9.5

4.7 (0–12)

67 (29–90)

9.5 (0–40)
61 (8–1,984)
298 (155–2,349)

4.7 ⫾ 2.4

7 (64)
4 (36)
7.7 (3.3–17.5)
⫺0.14 ⫾ 0.8

0.36 ⫾ 1.0
0.76 ⫾ 1.2
0.76 ⫾ 1.3

8 (67)
7.7 (3.3–16.5)

Other conditions
(n ⴝ 12)

* Values are the median (min–max) unless otherwise indicated. GC ⫽ glucocorticoids; DM ⫽ dermatomyositis; JIA ⫽ juvenile idiopathic arthritis; SLE ⫽ systemic lupus erythematosus; BMI ⫽ body
mass index; VAS ⫽ visual analog scale; ESR ⫽ erythrocyte sedimentation rate; HAES ⫽ Habitual Activity Estimation Scale; DXA ⫽ dual x-ray absorptiometry; L-spine ⫽ lumbar spine; BMD ⫽ bone
mineral density.
† Data available in 131 children.
‡ Reported in prednisone equivalents.

Demographic data
Girls, no. (%)
Age, years
Anthropometry
Height Z score, mean ⫾ SD
Weight Z score, mean ⫾ SD
BMI Z score, mean ⫾ SD
Pubertal stage, no. (%)†
Stage 1
Stage 2–5
Bone age, years
Age to bone age difference, mean
⫾ SD
Rheumatic condition characteristics
Disease activity, mean ⫾ SD 10cm VAS score
ESR, mm/hour
Days since diagnosis
Days since symptom onset
Physical activity level, HAES
Relative physical activity, % of
waking hours
Very active weekend hours
GC treatment, mean ⫾ SD
Cumulative GC dose (mg/m2)‡
Days taking GC, no.
Days between initial GC dose and
DXA assessment
L-spine BMD, mean ⫾ SD
Z score
Z score for bone age

Clinical characteristics

Overall cohort
(n ⴝ 134)

Table 1. Description of an inception cohort of children recently initiating GC for the treatment of rheumatic disorders*
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results of this model were then veriﬁed using a stepwise
model selection procedure that incorporated these same
factors as well as age, physical activity, calcium intake,
number of days on glucocorticoids, and time since diagnosis (log-transformed to reduce skewness).

RESULTS
Patient characteristics. Descriptions of the cohort are
provided in Tables 1 and 2. Of the children, 75% were
white; the other 25% were black (7%), aboriginal (5%),
South Asian (3%), and of other or mixed ethnicity (10%).
Height Z scores were comparable with the healthy average
for all disease subgroups (for the overall cohort P ⫽ 0.825,
for juvenile DM P ⫽ 0.559, for JIA P ⫽ 0.252, for SLE and
related conditions P ⫽ 0.292, for systemic arthritis P ⫽
0.255, for SV P ⫽ 0.174, and for other conditions P ⫽
0.248). Weight was signiﬁcantly above the healthy average
for the overall cohort (P ⫽ 0.006) and the SV subgroup
(P ⫽ 0.045), and BMI was increased in the overall cohort (P
⬍ 0.001), the SLE and related conditions subgroup (P ⫽
0.017), and the SV subgroup (P ⫽ 0.046).
Vertebral fracture and second metacarpal morphometry status. Of the 134 children, 9 (7% [95% CI
3.6 –12.3%]) were found to have a total of 13 vertebral
fractures. The children with fractures (5 boys, 4 girls)
ranged in age from 6 to 16.5 years. Of these children, 6 had
1 fracture, 2 children had 2 fractures, and 1 child had 3
fractures. Of the fractures, 9 were thoracic (4 at T6, 3 at T7,
and 2 at T8) and 4 were lumbar (2 at L1 and one each at L2
and L4). Nine of the fractures were mild (grade 1) anterior
wedge fractures, 3 were moderate (grade 2) wedge fractures, and 1 was a mild (grade 1) crush fracture. In the
juvenile DM subgroup (n ⫽ 30) there were 3 children with
fractures (10% [95% CI 4 –26%]), in the systemic arthritis
category (n ⫽ 22) there were 2 (9% [95% CI 3–28%]), in
the SLE and related conditions category (n ⫽ 26) there
were 2 (8% [95% CI 2–24%]), in the SV subgroup (n ⫽ 16)
there was 1 (6% [95% CI 1–28%]), and in the other conditions category (n ⫽ 12) there was 1 (8% [95% CI
1–35%]). None of the children with JIA (excluding systemic) manifested vertebral fractures (95% CI 0 –12%).
The 3 children with moderate (grade 2) fractures had Wegener’s granulomatosis, SLE, and systemic JIA. The 6 children with mild (grade 1) fractures had juvenile DM (n ⫽ 3),
systemic JIA, SLE, and scleroderma. Examples of mild and
moderate fractures that were representative of the fractures
detected in this cohort are presented in Figure 1. There
was no prior history of trauma in any of the patients.
A comparison of children with vertebral fractures and
those without is shown in Table 3. Back pain was reported
in 7 (78%) of the 9 children with fractures compared with
31 (25%) of the 125 children without (P ⫽ 0.002). A subset
of patients (131 of 134) also underwent palpation of the
T4 –L4 posterior spinous processes; only 8 of these 131
children reported pain on palpation, and none of these 8
children manifested vertebral fractures. Children with
fractures had a mean ⫾ SD L-spine BMD Z score of ⫺1.2 ⫾
1.0 compared with ⫺0.5 ⫾ 1.2 among those without (P ⫽
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Table 2. Speciﬁc diseases within diagnostic subgroups of
the total cohort (n ⴝ 134)*
Diagnostic subgroups

No. (%)

Juvenile DM
JIA (excluding systemic arthritis)
Polyarticular RF-positive arthritis
Polyarticular RF-negative arthritis
PsA
Enthesitis-related arthritis
Oligoarticular arthritis
Unclassiﬁed
SLE and related conditions
SLE
Overlap syndromes: mixed
connective tissue disease
JIA (systemic arthritis)
SV (excluding KD and HSP)
Takayasu arteritis
Wegener’s granulomatosis
Microscopic polyangiitis
Other vasculitis†
Other conditions
Generalized scleroderma
Localized scleroderma
Eosinophilic fasciitis

30 (22)
28 (21)
5 (18)
8 (29)
2 (7)
5 (18)
4 (14)
4 (14)
26 (20)
21 (81)
5 (19)
22 (16)
16 (12)
4 (25)
7 (44)
1 (6)
4 (25)
12 (9)
1 (8)
10 (84)
1 (8)

* RF ⫽ rheumatoid factor; PsA ⫽ psoriatic arthritis; SV ⫽ systemic
vasculitis; KD ⫽ Kawasaki disease; HSP ⫽ Henoch-Schönlein purpura. See Table 1 for additional deﬁnitions.
† Includes perinuclear antineutrophil cytoplasmic antibody
(pANCA)–positive vasculitis with recurrent pericarditis (n ⫽ 1),
pANCA-positive vasculitis with Goodpasture’s syndrome (n ⫽ 1),
central nervous system vasculitis (n ⫽ 1), and pANCA-positive
renal-limited vasculitis (n ⫽ 1).

0.082). For the children with fractures, the mean combined
second metacarpal cortical thickness Z score was ⫺0.23 ⫾
0.9 compared with 0.31 ⫾ 1.0 among those without (P ⫽
0.061), following adjustment for metacarpal length Z
score. Univariate logistic regression against prevalent vertebral fracture revealed that back pain was highly associated with increased odds for fracture (odds ratio 10.6 [95%
CI 2.1–53.8], P ⫽ 0.004) (Table 4).
Bone densitometry. L-spine BMD Z scores for the entire
cohort are presented in Table 1. There was no signiﬁcant
difference between bone age and chronological age (P ⫽
0.610). Similarly, L-spine BMD Z scores were no different
when bone age was substituted for chronological age (P ⫽
0.331). The mean L-spine BMD Z scores were signiﬁcantly
below the healthy average for the entire cohort (P ⬍ 0.001)
and for the following diagnostic subgroups: juvenile DM (P
⬍ 0.001), JIA excluding systemic JIA (P ⫽ 0.015), and
systemic arthritis (P ⫽ 0.002). Such differences were not
observed in the SLE and related conditions subgroup (P ⫽
0.768), the SV subgroup (P ⫽ 0.089), or the other conditions subgroup (P ⫽ 0.875). There was no signiﬁcant difference in the mean ⫾ SD L-spine BMD Z score between
those without fractures (⫺0.51 ⫾ 1.23; n ⫽ 125) compared
with those with mild (⫺0.76 ⫾ 0.92; n ⫽ 6) and moderate
vertebral fractures (⫺2.1 ⫾ 0.70; n ⫽ 3) (P ⫽ 0.079).
The following variables were signiﬁcant in a clinically
driven linear regression model that sought to determine
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Figure 1. A, 12-year-old boy with systemic juvenile idiopathic arthritis. Shown is a grade 1 crush fracture at L4, plus loss of endplate
parallelism and endplate interruption. The lumbar spine bone mineral density (BMD) Z score was ⫺1.4. B, 15-year-old girl with systemic
lupus erythematosus. Shown is a grade 2 wedge fracture at L1, plus loss of endplate parallelism and anterior cortical buckling. The lumbar
spine BMD Z score was ⫺1.7.

associations between relevant factors and age- and sexmatched L-spine BMD Z score: sex (␤ 0.67 [95% CI 0.25–
1.08], P ⫽ 0.002), height Z score (␤ 0.32 [95% CI 0.13–
0.50], P ⫽ 0.001), and BMI Z score (␤ 0.43 [95% CI 0.26 –
0.60], P ⬍ 0.001). The results of this model were conﬁrmed
using a stepwise model selection procedure, which produced the same results and explained 31% of the variability in the L-spine BMD Z score.

DISCUSSION
Our work highlights novel observations about bone morbidity in pediatric rheumatic conditions, because this pro-

spective study evaluated vertebral fracture status early in
the course of glucocorticoid exposure. We have documented a prevalent vertebral fracture rate of 7% in our
inception cohort, with rates of 10% in juvenile DM, 9% in
systemic arthritis, 8% in SLE and related conditions, 6%
in SV, and 8% in the other conditions subgroup. Although
fractures were not observed in the JIA (excluding systemic)
subgroup, our data suggest the potential for up to 12% of
children with JIA to manifest vertebral fracture if the results were inferred to a larger population of children with
JIA. Given that agreement between the radiologists on
vertebral fracture assignment was fair to moderate, the
protocol used in our study to assign vertebral fractures
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Table 3. Comparison of children with and without vertebral fractures*
Clinical characteristics
Demographic data
Girls, no. (%)‡
Age, years
Anthropometry
Height Z score, mean ⫾ SD
Weight Z score, mean ⫾ SD
BMI Z score, mean ⫾ SD
Pubertal stage, no. (%)§
Stage 1
Stage 2–5
Bone age, years
Second metacarpal morphometry, mean ⫾ SD Z scores
Metacarpal length
Percent cortical area
Combined cortical thickness
Rheumatic conditions characteristics
Disease activity (10-cm VAS), mean ⫾ SD
ESR, mean ⫾ SD mm/hour
Days since diagnosis, no.
Days since symptom onset, no.
Back pain, no. (%) yes‡
L-spine BMD Z score, mean ⫾ SD
Cumulative GC treatment
Dose in prednisone equivalents, mean ⫾ SD mg/m2
Days taking GC, mean ⫾ SD
Total calcium daily intake, mean ⫾ SD % of the DRI**
⬍50 (n ⫽ 4 with fractures, n ⫽ 0 without)
50–100 (n ⫽ 12 with fractures, n ⫽ 1 without)
ⱖ100 (n ⫽ 104 with fractures, n ⫽ 8 without)
Total vitamin D daily intake, mean ⫾ SD % of the DRI**
⬍50 (n ⫽ 30 with fractures, n ⫽ 2 without)
50–100 (n ⫽ 18 with fractures, n ⫽ 1 without)
ⱖ100 (n ⫽ 73 with fractures, n ⫽ 6 without)
HAES activity levels, very active weekend hours

Without fractures
(n ⴝ 125)

With fractures
(n ⴝ 9)

83 (66)
10.0 (1.4–16.9)

4 (44)
14.3 (6.4–16.5)

0.277
0.043

⫺0.29 ⫾ 0.9
⫺0.20 ⫾ 0.9
⫺0.13 ⫾ 1.1

0.267
0.154
0.213
1.000

0.04 ⫾ 1.0
0.31 ⫾ 1.2
0.40 ⫾ 1.2
65 (53)
58 (47)
10.0 (1.1–17.5)
0.35 ⫾ 1.1
0.21 ⫾ 0.9
0.31 ⫾ 1.0

4 (50)
4 (50)
13.5 (6–16)

P†

0.103

0.50 ⫾ 0.9
0.15 ⫾ 0.6
⫺0.23 ⫾ 0.9

0.553
0.628
0.061¶

5.6 ⫾ 2.7
40.5 ⫾ 31.2
23 (1–4,900)
146 (17–5,110)
31 (25)
⫺0.51 ⫾ 1.2

5.5 ⫾ 3.4
27.9 ⫾ 24.5
22 (3–1,902)
93 (19–2,268)
7 (77.8)
⫺1.2 ⫾ 1.0

0.887
0.234
0.407
0.771
0.002#
0.082

1,410 ⫾ 1,600
16.7 ⫾ 8.5

1,320 ⫾ 2,755
14.1 ⫾ 10.4

0.244
0.376

31 ⫾ 19
68 ⫾ 13
273 ⫾ 164

NA
70 (NA)
178 ⫾ 60

NA
0.923
0.042

24 ⫾ 15
74 ⫾ 14
170 ⫾ 65
1.1 (0–17)

30 ⫾ 25
74 (NA)
163 ⫾ 57
0 (0–4)

0.734
0.737
0.868
0.046

* Values are the median (min–max) unless otherwise indicated. DRI ⫽ Dietary Reference Intake; NA ⫽ not applicable. See Table 1 for additional
deﬁnitions.
† Statistical signiﬁcance determined by nonparametric test (Mann-Whitney U test with 2 independent samples). Level of signiﬁcance after Bonferroni
correction ⫽ 0.002.
‡ Statistical signiﬁcance determined by chi-square test or Fisher’s exact test.
§ Data available in 122 children. Statistical signiﬁcance determined by chi-square test or Fisher’s exact test.
¶ P value with adjustment for metacarpal length Z score by linear regression.
# Signiﬁcant at P ⱕ 0.002.
** By diet and supplement. Intake grouped into 3 groups based on the percentage relative to the DRI for age.

(which required agreement by 2 of 3 radiologists before a
vertebra was considered fractured) would tend to underestimate the prevalence of fracture; therefore, the fracture
prevalence rate may have been even slightly higher in
these disease groups.
The observations in this study have important clinical
implications. First, children with rheumatic conditions
can manifest clear evidence of bone fragility (i.e., vertebral
fractures) early in their disease course and exposure to
glucocorticoids. Second, back pain is a highly associated
clinical feature (though not universal, because 2 of the 9
children with fractures did not report such pain). That
vertebral fractures can be present in the absence of back
pain has been described in women with postmenopausal
OP (49), in children with long-standing histories of rheu-

matic conditions (11), and in childhood acute lymphoblastic leukemia (42). Overall, these results highlight that vertebral fractures are an under-recognized problem in
children who have recently initiated glucocorticoid therapy for rheumatic disorders.
We found that vertebral fractures were clustered in the
mid-thoracic and upper lumbar regions, similar to reports
in men and women with OP (50 –53) as well as recent
studies in children with rheumatic conditions (29) and
leukemia (42). It is suggested that this fracture pattern
results from the mechanical stresses induced by the natural kyphosis/lordosis of the spine (54). The location of
fractures in areas for which there is a known predilection
adds credence to our method of fracture determination.
The fact that wedge deformity was the most common mor-
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Table 4. Univariate logistic regression analysis of factors potentially associated with the
presence of vertebral fractures*
Children with rheumatic
disorders (n ⴝ 134)
Clinical parameter

OR (95% CI)

P†

Age
Sex, girls vs. boys
Height Z score
BMI Z score
Back pain
Disease activity, 10-cm VAS
Diagnosis, juvenile DM vs. others
Number of days since diagnosis, log-transformed
Total daily intake, ⱖ100% vs. ⬍100% of the DRI
Vitamin D
Calcium
Cumulative GC dose, g/m2
L-spine BMD Z score

1.2 (1.0–1.4)
0.4 (0.1–1.6)
0.7 (0.4–1.4)
0.7 (0.4–1.2)
10.6 (2.1–53.8)
1.0 (0.8–1.3)
1.8 (0.4–7.7)
0.9 (0.6–1.5)

0.062
0.195
0.334
0.185
0.004‡
0.887
0.420
0.693

1.3 (0.3–5.5)
1.3 (0.2–11.1)
1.0 (0.6–1.5)
0.6 (0.4–1.1)

0.708
0.806
0.876
0.090

* OR ⫽ odds ratio; 95% CI ⫽ 95% conﬁdence interval; DRI ⫽ Dietary Reference Intake. See Table 1 for
additional deﬁnitions.
† Level of signiﬁcance after Bonferroni correction ⫽ 0.004.
‡ Signiﬁcant at P ⱕ 0.004.

phologic ﬁnding is further in keeping with observations in
large populations of adults with vertebral fractures (54)
and in children with leukemia (42).
The few studies in the literature that have assessed the
status of vertebral fractures in children with rheumatic
conditions have been conducted at time points more distant in their disease course compared with our study.
Speciﬁcally, these reports have been cross-sectional or
retrospective, often in the face of long-term glucocorticoid
exposure, and have shown vertebral fracture prevalence
rates ranging from 10% to 50% (11,25,29,30). Our study
stands unique for its timing of patient evaluation within 30
days of glucocorticoid initiation. The only other study
conducted early in the course of the illness was by
Rouster-Stevens et al (18), who assessed spine areal BMD
by DXA in 37 children with untreated juvenile DM. They
found that 6 (18%) of 33 evaluable patients had L-spine
areal BMD Z scores less than ⫺1.5, and that the L-spine
BMD Z score was related to disease duration. Vertebral
fracture status was not evaluated in this cohort of patients.
Interestingly, we did not ﬁnd a link between disease duration and either vertebral fracture or L-spine BMD Z
score. Disease activity indices also showed a lack of association. These ﬁndings may reﬂect a lack of sufﬁcient
power to detect an association, a relatively short duration
from both the time since diagnosis and symptom onset for
most patients, and/or confounding effects of both underlying disease and short-term exposure to glucocorticoids
in our cohort.
When children with vertebral fractures in our study
were compared with those without, the only variable that
showed a strong relationship to fractures was back pain. Of
particular note is the borderline relationship between the
presence of vertebral fractures and L-spine BMD Z score.
In contrast, children with newly diagnosed leukemia demonstrated a strong relationship between L-spine BMD and
vertebral fractures, with the L-spine BMD Z score lower in

those with fractures, and falling as the grade of fracture
worsens (42). These disparate observations may be the
result of lower power due to the smaller number of fracture
events in rheumatic conditions soon after glucocorticoid
initiation compared with leukemia (7% versus 16%); on
the other hand, the more fulminate effect of the leukemic
process on bone may have greater impact on L-spine BMD
in the short term compared with the typically more insidious inﬂammatory state in recently diagnosed rheumatic
conditions.
Our study had 2 limitations that merit further consideration. First, back pain by report was determined, but the
location of the self-reported pain and the timing of pain
onset were not speciﬁed. We found that such pain was
highly correlated with vertebral fracture; however, without additional information as to the precise location of the
reported pain or the timing of onset, we could not further
correlate such parameters with the presence of vertebral
fracture or with the initiation of glucocorticoid therapy. A
subset of patients (131 of 134) underwent palpation of the
posterior spinous processes. While only 8 of the 131 children reported pain on palpation, none of these 8 children
manifested vertebral fractures. Given the small number of
children with palpation tenderness, we were unable to
draw further conclusions as to the relationships among
spine palpation tenderness, reported back pain, and vertebral fractures. At the present time, the clinical signiﬁcance of back pain and vertebral fractures in the absence of
localized vertebral tenderness in this population remains
unclear, particularly since the underlying disorders may
also be associated with back pain and tenderness.
The second limitation arises from the study design. Although our overall research program is predicated upon
within-subject change over time in key parameters such as
vertebral morphometry, this inaugural description of an
inception cohort is based on uncontrolled, cross-sectional
evaluation of spine status in relation to relevant clinical
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parameters. The lack of a control group gives rise to 2
issues in data interpretation. First, our spine BMD and
anthropometric Z scores have been generated through
comparison with historical, published normative data,
which may serve to underestimate such indices given
the rise in secular trends (55). Second, the frequency of
mild (grade 1) vertebral deformity in healthy children,
and thereby the clinical signiﬁcance of mild changes in
chronic illness, remains unknown. In postmenopausal
women, mild prevalent vertebral fractures are associated with an increased risk of future vertebral and hip
fractures (56,57), with prevalent vertebral fracture severity being the strongest independent risk factor. The relationship between prevalent grade 1 vertebral deformity at baseline in children with rheumatic conditions
and the potential for development of new or worsening
fractures will be assessed through further longitudinal
study of this cohort.
In conclusion, we have shown that children with a
variety of glucocorticoid-treated rheumatic conditions
can manifest vertebral fractures around the time of glucocorticoid initiation, and that back pain is a highly
correlated feature. Whether the fractures will undergo
reshaping or deterioration with ongoing glucocorticoid
treatment will be determined through longitudinal study.
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